secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001104659-26-025003
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence
--------------------------------------------------------------------------------

- CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.
- Acurx opens open-label pilot trial for ibezapolstat in multiply-recurrent CDI (up to 20 patients); first enrollment expected Q4 2026.
- Phase 2 data: ibezapolstat achieved 96% clinical cure (25/26) and 100% sustained cure with no recurrence at 1 month (25/25).
- Beneficial gut microbiome preservation and bile acid data suggest potential for single-agent treatment and prevention of rCDI.
- Company plans to seek FDA approval under LPAD pathway for rCDI treatment and prevention after Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926025003/0001104659-26-025003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926025003/tm268319d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-025003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer